Grail was founded in 2015 by Richard (Rick) Klausner, MD and Jeff Huber. The company filed its S-1 registration document with the SEC in September 2020 in advance of a planned Initial Public Offering. Subsequently in the same month, Illumia announced in a press release it had reached a definitive agreement to acquire Grail for $8 billion.
Grail is the developer of a pan-cancer screening test designed to detect cancer early. The company has raised approximately $2 billion in Venture Capital funding from investors including ARCH Venture Partners, Bezos Expeditions, Biomatics Capital, GV, Illumina, Foresite Capital Management, McKesson Ventures, Tencent, Amino Capital, Baillie Gifford, Decheng Capital, Dentsu Ventures, 6 Dimensions Capital, and Blue Pool Capital. Per company press releases, Grail last raised $390 million in May 2020 at a post-money valuation of $3.85 billion.
Grail does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.
The stock price for Grail will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 5/6/2020 | Series D | $4.26B | $XXX.XX | $XXX.XX |
| 5/21/2018 | Series C | $3.2B | $XXX.XX | $XXX.XX |
| 11/22/2017 | Series B | $2.35B | $XXX.XX | $XXX.XX |
| 1/8/2016 | Series A | $212.5MM | $XXX.XX | $XXX.XX |
